---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-005595"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2023-09-07T23:59:59+00:00"
generated_at: "2026-06-10T22:51:55.736747+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Corvus confirms soquelitinib Phase 3 trial for PTCL; initiation Q1 2024

## Summary
- FDA End-of-Phase meeting completed; trial design confirmed: 150 patients, 1:1 randomization, primary endpoint PFS.
- Enrollment of relapsed PTCL patients with ≤3 prior therapies; initiation expected in Q1 2024.
- Company to host conference call on Sept 7, 2023 to discuss trial plan and business updates.
- Soquelitinib is a selective ITK inhibitor; potential in hematologic cancers, solid tumors, autoimmune diseases.

## SEC filing metadata
- accession: 0001171843-23-005595
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2023-09-07T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000117184323005595/0001171843-23-005595-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000117184323005595/f8k_090623.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-005595
- JSON: https://secwatch.observer/filing/0001171843-23-005595.json
- Plain text: https://secwatch.observer/filing/0001171843-23-005595.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.